West Nile virus detected in mosquitoes in Northeast Philadelphia, health officials say
Officials said the disease was detected in mosquitoes near Pennypack Park during a routine surveillance for the virus.
The Department of Health has alerted area doctors and medical offices to look out for patients with symptoms of the virus and for residents to take precautions against the virus.
Those precautions include wearing long sleeves, using bug spray with DEET, and making sure you discard any standing water.
West Nile virus is a single-stranded RNA virus that causes West Nile fever. It is a member of the family Flaviviridae, from the genus Flavivirus, which also contains the Zika virus, dengue virus, and yellow fever virus. The virus is primarily transmitted by mosquitoes.
West Nile virus season in the United States generally runs from summer through fall, with the peak activity typically occurring in now through early September. This is when mosquito populations are at their highest and most active, especially during dusk and dawn.
The average number of West Nile virus cases in the U.S. varies annually, but the CDC reports that in 2022, 1,132 cases were reported. The disease is most common during the summer and early fall months. The CDC tracks West Nile virus cases through various surveillance systems, including human, animal, and mosquito surveillance.
All suspected and confirmed cases of West Nile virus should be reported to the Philadelphia Department of Public Health at 215-685-6741.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
23 minutes ago
- Medscape
Behavioral Therapy as First-Line for Bladder Control in PD?
TOPLINE: Structured behavioral therapy focused on pelvic floor muscle exercise was noninferior to treatment with solifenacin for alleviating overactive bladder symptoms in patients with Parkinson's disease (PD), new research showed. Because it was also associated with fewer side effects, especially falls, researchers recommended the behavioral therapy as a first-line treatment option. METHODOLOGY: This 12-week randomized noninferiority trial was conducted between 2018 and 2023 within four Veterans Affairs healthcare systems in the US. Overall, 77 patients diagnosed with PD and overactive bladder symptoms, as measured with an International Consultation on Incontinence Questionnaire overactive bladder module (ICIQ-OAB) symptom score ≥ 7, were included. All participants (mean age, 71 years; 84% men; 90% White individuals) were randomly assigned to receive either pelvic floor muscle exercise-based behavioral therapy with urge suppression training (n = 36) or 5 mg solifenacin daily with need-based titration up to 10 mg daily (n = 41). The primary outcome was ICIQ-OAB symptom score at 12 weeks. Secondary outcomes were ICIQ-OAB bother and quality of life scores and drug-related adverse events. TAKEAWAY: At 12 weeks, clinically significant improvement in ICIQ-OAB scores was observed across both treatment groups within a noninferiority margin of 15% (drug vs behavioral therapy: mean ICIQ-OAB score, 5.8 vs 5.5; P = .02). Both groups also had a reduction in symptom frequency, which was associated with a reduction in bother scores and an improvement in overactive bladder-related quality of life. Compared with the behavioral therapy group, the solifenacin group had a greater number of adverse events, including dry mouth (P = .002) and pain or burning during urination (P = .03). They also had a greater number of falls (6 vs 0). IN PRACTICE: 'The finding of increased falls in the solifenacin therapy group reinforces the need to carefully consider the risk-benefit ratio of medications for urinary symptoms, especially given the increased risk of falls among persons with PD. Results of this study suggest that behavioral therapy is an effective treatment option for persons with PD,' the investigators wrote. SOURCE: The study was led by Camille P. Vaughan, MD, Division of Geriatrics and Gerontology in the Department of Medicine, Emory University, Atlanta. It was published online on July 14 in JAMA Neurology. LIMITATIONS: The follow-up duration was limited to 12 weeks, restricting insight into longer-term outcomes. The cohort predominantly had male participants, reducing the generalizability of the findings, and the study relied on patient-reported data. Additionally, a higher dropout in the drug group led to nonrandom missing data, potentially biasing comparisons. DISCLOSURES: The study was funded by a grant from Veterans Affairs Rehabilitation Research and Development. Two investigators reported receiving grants from various sources during the conduct of the study. The other nine investigators reported having no relevant financial relationships. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
43 minutes ago
- Yahoo
Gabe Jackson gets up with the grounds crew to convert Covenant Health Park for soccer
Gabriel Jackson and Sophie Szydlik spent the day with the Covenant Health Park grounds crew and helped convert the Smokies field for One Knox SC.
New York Times
an hour ago
- New York Times
Corrections: July 23, 2025
An article on Sunday about the legal implications of being an organ donor misstated the number of Americans who are in the national donor registry. There are more than 173 million Americans in both state registries and the national registry, not the national registry alone. An article on Monday about the biotech company Sarepta Therapeutics and its distribution of a treatment for a deadly muscle-wasting disease misstated the date that Sarepta halted shipments of Elevidys for non-ambulatory Duchenne patients. Shipments were halted on June 15, not July 15. An article on Tuesday about President Trump urging two professional sports teams to change their names misstated the number of carved figures, known as the Guardians of Traffic, on the Hope Memorial Bridge in Cleveland. There are eight, not two. An obituary on Tuesday about the actor Kenneth Colley misstated the cause of the character Admiral Piett's death in the movie 'Return of the Jedi.' His ship crashes into the Death Star; he is not shot down by a Rebel fighter. Errors are corrected during the press run whenever possible, so some errors noted here may not have appeared in all editions. To contact the newsroom regarding correction requests, please email nytnews@ To share feedback, please visit Comments on opinion articles may be emailed to letters@ For newspaper delivery questions: 1-800-NYTIMES (1-800-698-4637) or email customercare@
